Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics Inc (NQ: PTGX )

46.58 +0.43 (+0.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 773,070
Open 47.10
Bid (Size) 46.55 (9)
Ask (Size) 46.56 (1)
Prev. Close 46.15
Today's Range 46.16 - 47.61
52wk Range 13.72 - 48.00
Shares Outstanding 58,904,585
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential. 
Via Benzinga
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Via ACCESSWIRE

Performance

YTD
+98.89%
+98.89%
1 Month
+11.97%
+11.97%
3 Month
+45.52%
+45.52%
6 Month
+67.01%
+67.01%
1 Year
+170.97%
+170.97%

More News

Read More
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
Via ACCESSWIRE
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
Via ACCESSWIRE
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
Via ACCESSWIRE
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
Via ACCESSWIRE
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Via Benzinga
AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
Via ACCESSWIRE
3 Growth Stocks No One Is Watching (But They Should Be)
Via InvestorPlace
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
Via ACCESSWIRE
The 3 Best Biotech Stocks to Buy in June 2024
Via InvestorPlace
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
Via ACCESSWIRE
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
Via ACCESSWIRE
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
Via ACCESSWIRE
Turnstone Biologics Appoints William Waddill to its Board of Directors
From Turnstone Biologics Corp.
Via GlobeNewswire
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
Via ACCESSWIRE
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
Via ACCESSWIRE
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.